TenX Keane Acquisition - TENKU STOCK NEWS

TenX Keane Acquisition shareholders have approved the merger with Citius Pharmaceuticals' oncology subsidiary to form Citius Oncology, Inc. The vote took place at an extraordinary general meeting on August 2, 2024. The newly combined company is expected to trade on Nasdaq under the Citius Oncology name. This merger aims to support the commercialization of LYMPHIR, pending approval, and explore additional oncology assets. The transaction is anticipated to provide Citius Oncology with improved access to public equity markets. Subject to closing conditions, the merger is expected to be completed in the coming weeks. This strategic move positions Citius Oncology to advance its oncology pipeline and potentially strengthen its market presence in the biopharmaceutical sector.

TenX Keane Acquisition (TENKU, TENK, TENKR) proposes to amend its Amended and Restated Memorandum and Articles of Association to extend the deadline for a business combination up to November 18, 2024, with sponsor contributions if the extension is approved.

Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) completes Mino-Lok® Pivotal Phase 3 trial enrollment, with topline data expected in 2Q 2024. LYMPHIR™ BLA resubmission on track for early 2024. The company reports fiscal full year 2023 business and financial results, highlighting progress in pipeline development, clinical trials, and merger activities. Financially, the company has $26.5 million in cash and cash equivalents, with R&D and G&A expenses detailed for the full year 2023.

Citius Pharmaceuticals, Inc. and TenX Keane Acquisition have entered into a definitive agreement for a proposed merger. Citius Pharma will receive $675 million in equity of Citius Oncology and retain approximately 90% majority control. The transaction is expected to close in the first half of 2024. Citius Oncology will focus on developing and commercializing novel targeted oncology therapies, with LYMPHIR as its flagship product.

Citius Pharmaceuticals, Inc. and TenX Keane Acquisition have entered into a definitive agreement for a proposed merger. Citius Pharma will receive $675 million in equity of Citius Oncology and retain majority control. The merger is expected to close in the first half of 2024. Citius Oncology will focus on developing and commercializing novel targeted oncology therapies, with LYMPHIR as its flagship product. The transaction will provide Citius Oncology with improved access to the public equity markets.

TenX Keane Acquisition extends the date for completing its initial business combination and receives an extension fee of $660,000.

TenX Keane Acquisition announces extension of initial business combination date and deposit of $660,000 into trust account.

TenX Keane Acquisition (NASDAQ:TENKU) announced the closing of its initial public offering (IPO) of 6,600,000 units at an offering price of $10.00 per unit, generating $66,000,000 in gross proceeds. The IPO included a partial exercise of the underwriter's over-allotment option for 600,000 units. Each unit consists of one ordinary share and one right, with rights entitling holders to receive two-tenths of one share upon the initial business combination. The units began trading on NASDAQ under the symbol TENKU on October 14, 2022.